Catalog No.
DVV00108
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
STI-1499, STI 1499, STI1499, COVI-SHIELD
Clone ID
STI-1499
Note
For research use only. Not suitable for clinical or therapeutic use.
Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies., PMID:40346118
A compartmentalization-free microfluidic digital assay for detecting picogram levels of protein analytes., PMID:40351019
Evaluation of an E. coli-expressed spike protein-based in-house ELISA system for assessment of antibody responses after COVID-19 infection and vaccination., PMID:40352206
Mimicking immune complexes for efficient antibody responses., PMID:40356891
Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals., PMID:40358138
Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity., PMID:40359129
SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform., PMID:40360482
Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice., PMID:40360777
A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2 in Sprague-Dawley rats., PMID:40366666
Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2 Virus-Like particle (SC2-VLP) infectivity., PMID:40374718
A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses., PMID:40379714
Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants., PMID:40383030
Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination., PMID:40386778
Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies., PMID:40387363
The Combination of TLR4 and TLR9 Agonists with Self-Amplifying RNA Lipid Nanoparticles Leads to a More Powerful Immune Response Against SARS-CoV-2., PMID:40401447
Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles., PMID:40402246
Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies., PMID:40403696
Construction of a variable fragment (Fv)-immunoglobulin A (IgA) anti-receptor binding domain (RBD) SARS-CoV-2 library based on IgA from Indonesian COVID-19 survivors., PMID:40403817
Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster., PMID:40406109
Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains., PMID:40408899
Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model., PMID:40410742
Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant., PMID:40413500
Is SARS-CoV-2 Spike Evolution Being Retargeted at the N-Terminal Domain?, PMID:40415355
Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate., PMID:40425664
Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen., PMID:40429644
Efficient Searches in Protein Sequence Space Through AI-Driven Iterative Learning., PMID:40429882
Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies., PMID:40430736
The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil., PMID:40430765
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652
Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678
A Luciferase-Based Approach for Functional Screening of 5' and 3' Untranslated Regions of the mRNA Component for mRNA Vaccines., PMID:40432139
Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929
ACE2, a therapeutic target of COVID-19, needs to be treated with caution., PMID:40439840
Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota., PMID:40444030
Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections., PMID:40447072
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 'Patria' vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version., PMID:40458417
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations., PMID:40458889
Tracking the dynamics of antibody production against the SARS-CoV-2 virus after two doses of the mRNA vaccine BNT162b2., PMID:40461246
Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response., PMID:40461490
SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023., PMID:40462062
Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study., PMID:40462400
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern., PMID:40463385
Serum Levels of IL-21 and IL-27 Do not Reflect differential Avidity of Anti-SARS-CoV-2 IgG Antibodies in Symptomatic and Asymptomatic COVID-19 Patients., PMID:40471646
Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2., PMID:40481111
Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry., PMID:40483334
Long COVID-19 autoantibodies and their potential effect on fertility., PMID:40496870
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720
Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates., PMID:40498855
For research use only. Not for human or drug use.
